Prot #TAK-375SL_301: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg and 0.4 mg as an Adjunctive Therapy in

Project: Research project

Project Details

Effective start/end date12/13/1212/13/15


  • Covance Inc. (Prot #TAK-375SL_301 // Prot #TAK-375SL_301)
  • Takeda Development Center Americas, Inc. (Prot #TAK-375SL_301 // Prot #TAK-375SL_301)